[go: up one dir, main page]

WO1999003976A3 - Method of treating leukocytes, leukocyte compositions and methods of use thereof - Google Patents

Method of treating leukocytes, leukocyte compositions and methods of use thereof Download PDF

Info

Publication number
WO1999003976A3
WO1999003976A3 PCT/US1998/015067 US9815067W WO9903976A3 WO 1999003976 A3 WO1999003976 A3 WO 1999003976A3 US 9815067 W US9815067 W US 9815067W WO 9903976 A3 WO9903976 A3 WO 9903976A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
leukocytes
leukocyte
treating
Prior art date
Application number
PCT/US1998/015067
Other languages
French (fr)
Other versions
WO1999003976A2 (en
Inventor
William M Greenman
Joshua A Grass
Sohel Talib
Adonis Stassinopoulos
Derek J Hei
John E Hearst
Original Assignee
Cerus Corp
William M Greenman
Joshua A Grass
Sohel Talib
Adonis Stassinopoulos
Derek J Hei
John E Hearst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp, William M Greenman, Joshua A Grass, Sohel Talib, Adonis Stassinopoulos, Derek J Hei, John E Hearst filed Critical Cerus Corp
Priority to EP98936943A priority Critical patent/EP1005531A2/en
Priority to CA002296366A priority patent/CA2296366A1/en
Priority to JP2000503182A priority patent/JP2003520563A/en
Priority to AU85776/98A priority patent/AU748074B2/en
Publication of WO1999003976A2 publication Critical patent/WO1999003976A2/en
Publication of WO1999003976A3 publication Critical patent/WO1999003976A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods and compositions for treating leukocytes to arrest proliferation of the leukocytes and render them ineffective in eliciting graft-versus-host disease (GVHD), but effective to enhance engraftment of allongeneic donor cells and promote destruction of diseased cells or pathogens. Leukocyte compositions and methods of use of these compositions in alleviating disease, facilitating various types of immune reconstitution and immunotherapy, and enhancing engraftment of allogeneic donor cells, are also provided.
PCT/US1998/015067 1997-07-21 1998-07-21 Method of treating leukocytes, leukocyte compositions and methods of use thereof WO1999003976A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98936943A EP1005531A2 (en) 1997-07-21 1998-07-21 Method of treating leukocytes, leukocyte compositions and methods of use thereof
CA002296366A CA2296366A1 (en) 1997-07-21 1998-07-21 Method of treating leukocytes, leukocyte compositions and methods of use thereof
JP2000503182A JP2003520563A (en) 1997-07-21 1998-07-21 Methods for treating leukocytes, leukocyte compositions and methods of using the same
AU85776/98A AU748074B2 (en) 1997-07-21 1998-07-21 Method of treating leukocytes, leukocyte compositions and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5359997P 1997-07-21 1997-07-21
US60/053,599 1997-07-21
US11970798A 1998-07-20 1998-07-20
US09/119,707 1998-07-20

Publications (2)

Publication Number Publication Date
WO1999003976A2 WO1999003976A2 (en) 1999-01-28
WO1999003976A3 true WO1999003976A3 (en) 1999-05-27

Family

ID=26732039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015067 WO1999003976A2 (en) 1997-07-21 1998-07-21 Method of treating leukocytes, leukocyte compositions and methods of use thereof

Country Status (6)

Country Link
EP (1) EP1005531A2 (en)
JP (1) JP2003520563A (en)
CN (1) CN1270630A (en)
AU (1) AU748074B2 (en)
CA (1) CA2296366A1 (en)
WO (1) WO1999003976A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8409564B2 (en) 1999-10-05 2013-04-02 Universite De Montreal Rhodamine derivatives for photodynamic diagnosis and treatment
BR0014135A (en) * 1999-10-05 2002-05-21 Univ Montreal Photoactivable pharmaceutical composition for selective destruction and / or inactivation of immunologically reactive cells, use thereof, and methods for preventing graft-versus-host disease associated with allogeneic stem cell transplantation in a patient, for treatment of immune disorder in one patient and to assess the transport mechanism of immune and / or malignant cells
AU2002218019A1 (en) * 2000-11-03 2002-05-15 Nexell Therapeutics Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
DE10112851C1 (en) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogeneic anti-tumor vaccine with HLA-haplo-identical antigen-presenting cells
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
ATE552843T1 (en) 2003-02-06 2012-04-15 Aduro Biotech LISTERIA WHOSE INVESTIGATION INTO NON-PHAGOCYTIC CELLS IS ATTENUATED, VACCINES CONTAINING THESE LISTERIA AND THEIR USES
DK2352756T3 (en) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen High-affinity T cell receptor and its use
DE102011085695A1 (en) * 2011-11-03 2013-05-08 Jörg Pohl One-time dosed oxazaphosphorines for the treatment of diseases
US20130252227A1 (en) * 2012-03-20 2013-09-26 Fenwal, Inc. Apparatus and Method for Providing Cryopreserved ECP-Treated Mononuclear Cells
US20190224494A1 (en) * 2012-03-20 2019-07-25 Fenwal, Inc. Apparatus and method for batch photoactivation of mononuclear cells with cryopreservation
WO2016073381A1 (en) * 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
EP3058957A1 (en) * 2015-02-19 2016-08-24 Kiadis Pharma Intellectual Property BV Improved photodynamic process and product obtained therefrom
CN104788373A (en) * 2015-05-06 2015-07-22 武汉大学 Method for synthesizing compound S-303 hydrochloride
CA2995582A1 (en) 2015-08-19 2017-02-23 Children's Research Institute, Children's National Medical Center Compositions and methods for treating graft versus host disease
US11679193B2 (en) 2017-12-20 2023-06-20 Fenwal, Inc. System and method of collecting and infusing an apoptotic white blood cell component and a transplant component
FR3082730B1 (en) * 2018-06-21 2022-04-22 Med Inn Pharma METHOD OF RESOLVING PRO-TUMOR INFLAMMATION USING A PHARMACEUTICAL PREPARATION
CN109337758A (en) * 2018-11-30 2019-02-15 广西科技大学 A method for capturing and eliminating aflatoxin in oil based on UV-enhanced DNA and aflatoxin chimerism

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284409A2 (en) * 1987-03-27 1988-09-28 THERAKOS, Inc. Active specific immune suppression
WO1996039820A1 (en) * 1995-06-07 1996-12-19 Cerus Corporation Methods of inactivating leukocytes and inhibiting cytokine production in blood products
US5651993A (en) * 1992-11-18 1997-07-29 Yale University Specific immune system modulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284409A2 (en) * 1987-03-27 1988-09-28 THERAKOS, Inc. Active specific immune suppression
US5651993A (en) * 1992-11-18 1997-07-29 Yale University Specific immune system modulation
WO1996039820A1 (en) * 1995-06-07 1996-12-19 Cerus Corporation Methods of inactivating leukocytes and inhibiting cytokine production in blood products

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GAUS H. ET AL.: "Superantigen-induced anergy of Vbeta8sup + CD4sup + T cells induces functional but non-proliferative T cells in vivo", IMMUNOLOGY, vol. 83, no. 3, 1994, gb, pages 333 - 340, XP002094963 *
GRASS J. ET AL.: "Inactivation of T-cells with psoralens and UVA in human platelet concentrates", BLOOD, vol. 86, no. 10 suppl.1, - 1995, pages 542a, XP002094969 *
GRASS J. ET AL.: "Prevention of transfusion-associated graft versus host disease (TA-GVHD) by photochemical treatment", BLOOD, vol. 88, no. 10 Suppl.1, 1996, pages 627a, XP002094968 *
GRASS J.A. ET AL.: "Inactivation of leucocytes in platelet concentrates by photochemical treatment with psoralen plus UVA", BLOOD, vol. 91, no. 6, 1998, pages 2180 - 2188, XP002094967 *
HALSTENSEN T., BRANDTZAEG P.: "Activated T lymphocytes in the celiac lesion: Non proliferative activation (CD25) of CD24 positive apha/beta cells in the lamina propria but proliferation (Ki-67) of alpha/beta and gamma/delta cells in the epithelium", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, no. 2, 1993, pages 505 - 510, XP002094962 *
KOZENITZKY L. ET AL.: "Immunomodulatory effects of AS101 on interleukin-2 production and T-lymphocyte function of lymphocytes treated with psoralens and ultraviolet A", PHOTODERMATOLOGY, PHOTOIMMUNOLOGY & PHOTOMEDICINE, vol. 9, no. 1, 1992, pages 24 - 28, XP002094960 *
MONTERO R. ET AL.: "AS-101: a modulator of in vitro T-cel proliferation", ANTI-CANCER DRUGS, vol. 4, no. 3, 1993, pages 351 - 354, XP002094966 *
ULLRICH S.E.: "Photoinactivation of t-cell function with psoralen and uvA radiation suppresses the induction of experimental murine graf-versus-host disease accross Major Histocompatibility barriers", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 96, no. 3, 1991, pages 303 - 308, XP002094961 *
WINKELSTEIN A.: "Murine B-lymphocyte colony formation: the effects of cyclophosphamide and azathiopirine", IMMUNOLOGY, vol. 46, - 1982, gb, pages 827 - 832, XP002094965 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US12064537B2 (en) 2017-03-03 2024-08-20 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US12214092B2 (en) 2017-12-29 2025-02-04 Cerus Corporation Systems and methods for treating biological fluids
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12343436B2 (en) 2019-06-28 2025-07-01 Cerus Corporation System and methods for implementing a biological fluid treatment device

Also Published As

Publication number Publication date
JP2003520563A (en) 2003-07-08
CN1270630A (en) 2000-10-18
EP1005531A2 (en) 2000-06-07
CA2296366A1 (en) 1999-01-28
AU748074B2 (en) 2002-05-30
WO1999003976A2 (en) 1999-01-28
AU8577698A (en) 1999-02-10

Similar Documents

Publication Publication Date Title
WO1999003976A3 (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
ZA936491B (en) Soluble ligands for cd40.
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2003083041A3 (en) Cripto-specific antibodies
DE60032622D1 (en) COMPOSITION AND METHOD FOR CANCER ANTIGEN IMMUNOTHERAPY
ATE439137T1 (en) TREATMENT OF HEMATOLOGICAL DISORDERS
WO2000023955A8 (en) Virus-like particles for the induction of autoantibodies
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
NO943967D0 (en) Suppression of proliferative responses and induction of tolerance by polymorphic class II MHC allopeptides
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
AU7361900A (en) Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
IL99778A0 (en) Compositions for the treatment of cell proliferation disorders
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
KR890700353A (en) Immunosuppression of the immune toxin
CA2346735A1 (en) Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
WO2002017935A3 (en) A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
GB2331460B (en) Pharmaceutical composition for the treatment of hepatitis B comprising extract of phyllanthus ussuriensis and/or phyllanthus urinaria
WO2002015915A3 (en) Method for inducing an anti-tumor and anti-cachexia immune response in mammals
NO20010488L (en) Method of ex vivo treatment of allogeneic and xenogenic T cells with gp39 antagonists
WO2004003153A3 (en) Live replicating spumavirus vector
DE50305753D1 (en) METHOD AND AGENT FOR THE PREVENTION, INHIBITION AND THERAPY OF CANCER DISEASES
IL160412A0 (en) Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer
UA32358A (en) Method for treatment of hypertension

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98809097.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2296366

Country of ref document: CA

Ref document number: 2296366

Country of ref document: CA

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 85776/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998936943

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998936943

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 85776/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998936943

Country of ref document: EP